The Charles R. Bronfman Institute for Personalized Medicine is an interdisciplinary institute to advance personalized health and health care. IPM is dedicated to fulfilling three goals:

• Provide clinical and translational investigators with greater and easier access to high quality, standardized biospecimen collections, linked with full clinical information.
• Provide an academic research home and technology support for discovering clinically important genotype-phenotype associations through interdisciplinary, translational genomics programs.
• Facilitate clinical development of gene-based diagnostics and risk assessment algorithms and evaluate their impact on health care delivery at the patient and population level.

Mount Sinai is an international leader in the study of the genetic underpinnings of human disease. It has always been known for emphasizing the role of research in patient care and the institution has an undisputed advantage in patient care, with large, well-characterized patient populations, as well as in research with established, NIH-funded patient databases and registries.

Today, Mount Sinai's disease-oriented research centers are home to many ongoing clinical trials, staffed with internationally renowned clinical investigators and clinicians, which provide numerous unique opportunities to advance personalized medicine.